In a filing, Janux Therapeutics Inc revealed its President and CEO Campbell David Alan unloaded Company’s shares for reported $1.0 million on Dec 03 ’24. In the deal valued at $67.00 per share,15,000 shares were sold. As a result of this transaction, Campbell David Alan now holds 242,054 shares worth roughly $14.92 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Campbell David Alan sold 25,000 shares, generating $1,289,879 in total proceeds. Upon selling the shares at $51.60, the President and CEO now owns 257,054 shares.
Before that, Reardon Tighe bought 5,202 shares. Janux Therapeutics Inc shares valued at $277,987 were divested by the FORMER OFFICER at a price of $53.44 per share.
H.C. Wainwright reiterated its Janux Therapeutics Inc [JANX] rating to a Buy in a research note published on December 03, 2024; the price target was $70. A number of analysts have revised their coverage, including BTIG Research’s analysts, who remained covering the stock and in early December has reiterated a ‘”a Buy”‘ rating for it. Leerink Partners began covering JANX with “an Outperform” recommendation on November 22, 2024. UBS started covering the stock on October 24, 2024. It rated JANX as “a Buy”.
Price Performance Review of JANX
On Monday, Janux Therapeutics Inc [NASDAQ:JANX] saw its stock fall -5.14% to $61.65. Over the last five days, the stock has gained 53.43%. Janux Therapeutics Inc shares have risen nearly 474.56% since the year began. Nevertheless, the stocks have risen 554.46% over the past one year. While a 52-week high of $71.71 was reached on 12/05/24, a 52-week low of $7.79 was recorded on 02/05/24. SMA at 50 days reached $51.28, while 200 days put it at $46.11.
Levels Of Support And Resistance For JANX Stock
The 24-hour chart illustrates a support level at 60.11, which if violated will result in even more drops to 58.57. On the upside, there is a resistance level at 64.24. A further resistance level may holdings at 66.83. The Relative Strength Index (RSI) on the 14-day chart is 60.71, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 11.24, which suggests price will go up in the next trading period. Percent R suggests that price movement has been low at 31.74%. Stochastics %K at 76.66% indicates the stock is a holding.
How much short interest is there in Janux Therapeutics Inc?
A steep rise in short interest was recorded in Janux Therapeutics Inc stocks on 2024-11-15, dropping by -0.15 million shares to a total of 4.19 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 4.33 million shares. There was a decline of -3.5%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 06, 2024 when Stifel began covering the stock and recommended ‘”a Buy”‘ rating along with a $70 price target.
